Incyte Corp

Change company Symbol lookup

Select an option...

INCY Incyte Corp

MDIA Mediaco Holding Inc

SWVLW Swvl Holdings Equity Warrant Exp 31st Mar 2027 *W EXP 03/31/2027

SCBCX Franklin Multi-Asset Conservative Growth Fund C

BUI BlackRock Utilities, Infrastructure & Power Opportunities Trust

FDEU First Trust Dynamic Europe Equity Income

DOCU DocuSign Inc

DHCAU DHC Acquisition Corp

BCH Banco de Chile

NLRCF Northern Lights Resources Corp

Go

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts commercial and clinical development operations from its European headquarters in Morges, Switzerland, and Japanese office in Tokyo and Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. The other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise is comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib) and ICLUSIG (ponatinib), as well as other clinical development programs. Its Dermatology commercial franchise is comprised of OPZELURA (ruxolitinib) cream.